Abstrakt

Lipoic acid (LA) is a natural compound present in food and used as a dietary supplement. LA is endogenously synthetized in small amounts from octanoid acid in the mitochondria. This compound occurs naturally in vegetables such as spinach, broccoli and in animal tissues, in the kidneys, heart and liver. It has been shown that LA is a cofactor in the multienzyme complexes that are responsible for oxidative decarboxylation of α- ketoacids. LA and its reduced form, dihydrolipoic acid (DHLA), have many biological functions leading to a wide variety of actions such as anti-inflammation and antioxidant protection, scavenging of reactive oxygen species, regenerating other antioxidant agents, such as vitamins C and E, and cytosolic glutathione, chelating the transitional metal ions (e.g. iron and copper), and modulating the signal transduction of nuclear factor. Many authors regard LA as a potentially useful agent in the treatment and/or prevention of many diseases such as diabetes mellitus, overweight, obesity, hypertension, heart diseases, inflammation. This review concentrates on the role of LA in the treatment of diabetes mellitus, obesity, inflammation and blood pressure regulation. LA can be considered as a potentially useful drug in treatment of many diseases, particularly those related to excessive production of free radicals.

Przypisy

• 1. Abdali D., Samson S.E., Grover A.K.: How effective are antioxidantsupplements in obesity and diabetes? Med. Princ. Pract., 2015;24: 201–215
  Google Scholar
• 2. Alexopoulos N., Katritsis D., Raggi P.: Visceral adipose tissue as asource of inflammation and promoter of atherosclerosis. Atherosclerosis,2014; 233: 104–112
  Google Scholar
• 3. Allison S.J.: Hypertension: Oxidative stress and immune activationin hypertension. Nat. Rev. Nephrol., 2016; 12: 4
  Google Scholar
• 4. Ametov A.S., Barinov A., Dyck P.J., Hermann R., Kozlova N., LitchyW.J., Low P.A., Nehrdich D., Novosadova M., O’Brien P.C., ReljanovicM., Samigullin R., Schutte K., Strokov I., Tritschler H.J., et al.: Thesensory symptoms of diabetic polyneuropathy are improved withα-lipoic acid. The SYDNEY Trial. Diabetes Care, 2003; 26: 770–776
  Google Scholar
• 5. Ansar H., Mazloom Z., Kazemi F., Hejazi N.: Effect of α-lipoic acidon blood glucose, insulin resistance and glutathione peroxidase oftype 2 diabetic patients. Saudi Med. J., 2011; 32: 584–588
  Google Scholar
• 6. Babizhayev M.A., Strokov I.A., Nosikov V.V., Savel’yeva E.L., SitnikovV.F., Yegorov Y.E., Lankin VZ.: The role of oxidative stress in diabeticneuropathy: Generation of free radical species in the glycationreaction and gene polymorphisms encoding antioxidant enzymesto genetic susceptibility to diabetic neuropathy in population oftype I diabetic patients. Cell. Biochem. Biophys., 2015; 71: 1425–1443
  Google Scholar
• 7. Bakker W., Eringa E.C., Sipkema P., van Hinsbergh V.W.: Endothelialdysfunction and diabetes: roles of hyperglycemia, impairedinsulin signaling and obesity. Cell Tissue Res., 2009; 335: 165–189
  Google Scholar
• 8. Biewenga G.P., Haenen G.R., Bast A.: The pharmacology of theantioxidant lipoic acid. Gen. Pharmacol., 1997; 29: 315–331
  Google Scholar
• 9. Bouchard L., Rabasa-Lhoret R., Faraj M., Lavoie M.E., Mill J., PerusseL., Vohl M.C.: Differential epigenomic and transcriptomic responsesin subcutaneous adipose tissue between low and high respondersto caloric restriction. Am. J. Clin. Nutr., 2010; 91: 309–320
  Google Scholar
• 10. Bramanti V., Tomassoni D., Bronzi D., Grasso S., Curro M., AvitabileM., Li Volsi G., Renis M., Ientile R., Amenta F., Avola R.: α-lipoic acidmodulates GFAP, vimentin, nestin, cyclin D1 and MAP-kinase expressionin astroglial cell cultures. Neurochem. Res., 2010; 35: 2070–2077
  Google Scholar
• 11. Campion J., Milagro F.I., Martinez J.A.: Individuality and epigeneticsin obesity. Obes. Rev., 2009; 10: 383–392
  Google Scholar
• 12. Carbonelli M.G., Renzo L.D., Bigioni M., Di Daniele N., De LorenzoA., Fusco M.A.: α-lipoic acid supplementation: A tool for obesitytherapy? Curr. Pharm. Des., 2010; 16: 840–846
  Google Scholar
• 13. Chaudhary P., Marracci G.H., Bourdette D.N.: Lipoic acid inhibitsexpression of ICAM-1 and VCAM-1 by CNS endothelial cells andT cell migration into the spinal cord in experimental autoimmuneencephalomyelitis. J. Neuroimmunol., 2006; 175: 87–96
  Google Scholar
• 14. Chen L., Magliano D.J., Zimmet P.Z.: The worldwide epidemiologyof type 2 diabetes mellitus-present and future perspectives. Nat.Rev. Endocrinol., 2011; 8: 228–236
  Google Scholar
• 15. Cheserek M.J., Wu G., Li L., Li L., Karangwa E., Shi Y., Le G.: Cardioprotectiveeffects of lipoic acid, quercetin and resveratrol onoxidative stress related to thyroid hormone alterations in long-termobesity. J. Nutr. Biochem., 2016; 33: 36–44
  Google Scholar
• 16. Choi K.H., Park M.S., Kim H.S., Kim K.T., Kim H.S., Kim J.T., Kim B.C.,Kim M.K., Park J.T., Cho K.H.: α-lipoic acid treatment is neurorestorativeand promotes functional recovery after stroke in rats. Mol. Brain, 2015; 8: 9
  Google Scholar
• 17. Choi K.H., Park M.S., Kim J.T., Kim H.S., Kim J.H., Nam T.S., ChoiS.M., Lee S.H., Kim B.C., Kim M.K., Cho K.H.: Lipoic acid use and functionaloutcomes after thrombolysis in patients with acute ischemicstroke and diabetes. PLoS One, 2016; 11: e0163484
  Google Scholar
• 18. Davidson E.P., Coppey L.J., Shevalye H., Obrosov A., Kardon R.H.,Yorek M.A.: Impaired corneal sensation and nerve loss in a type 2 ratmodel of chronic diabetes is reversible with combination therapy ofmenhaden oil, α-lipoic acid, and enalapril. Cornea, 2017; 36: 725–731
  Google Scholar
• 19. de Champlain J., Wu R., Girouard H., Karas M., El-Midaoui A.,Laplante M.A., Wu L.: Oxidative stress in hypertension. Clin. Exp.Hypertens, 2004; 26: 593–601
  Google Scholar
• 20. Derosa G., D’Angelo A., Romano D., Maffioli P.: A clinical trialabout a food supplement containing α-lipoic acid on oxidative stressmarkers in type 2 diabetic patients. Int. J. Mol. Sci., 2016; 17: 1802
  Google Scholar
• 21. Dinicola S., Proietti S., Cucina A., Bizzarri M., Fuso A.: α-lipoicacid downregulates IL-1β and IL-6 by DNA hypermethylation in SK–N-BE neuroblastoma cells. Antioxidants, 2017; 6: E74
  Google Scholar
• 22. Dudek M., Razny K., Bilska-Wilkosz A., Iciek M., Sapa J., WłodekL., Filipek B.: Hypotensive effect of α-lipoic acid after a single administrationin rats. Anatol. J. Cardiol., 2016; 16: 306-309
  Google Scholar
• 23. Duncan R.E., Ahmadian M., Jaworski K., Sarkadi-Nagy E., SulH.S.: Regulation of lipolysis in adipocytes. Annu. Rev. Nutr., 2007;27: 79-101
  Google Scholar
• 24. Dworacka M., Iskakova S., Krzyżagorska, E., Wesołowska A., KurmambayevY., Dworacki G.: α-lipoic acid modifies circulating angiogenicfactors in patients with type 2 diabetes mellitus. Diabetes Res.Clin. Pract., 2015; 107: 273-279
  Google Scholar
• 25. El Midaoui A., de Champlain J.: Prevention of hypertension,insulin resistance, and oxidative stress by α-lipoic acid. Hypertension,2002; 39: 303-307
  Google Scholar
• 26. EL-Senousey H.K., Chen B., Wang J.Y., Atta A.M., Mohamed F.R.,Nie Q.H.: Effects of dietary vitamin C, vitamin E, and α-lipoic acidsupplementation on the antioxidant defense system and immune-related gene expression in broilers exposed to oxidative stress bydexamethasone. Poult. Sci., 2018; 97: 30-38
  Google Scholar
• 27. Ergur B.U., Micili S.C., Yilmaz O., Akokay P.: The effects of aα-lipoic acid on aortic injury and hypertension in the rat remnantkidney (5/6 nephrectomy) model. Anatol. J. Cardiol., 2015: 15: 443-449
  Google Scholar
• 28. Fair A.M., Montgomery K.: Energy balance, physical activity,and cancer risk. Methods Mol. Biol., 2009; 472: 57-88
  Google Scholar
• 29. Farr S.A., Poon H.F., Dogrukol-Ak D., Drake J., Banks W.A., EyermanE., Butterfield D.A., Morley J.E.: The antioxidants α-lipoic acidand N-acetylcysteine reverse memory impairment and brain oxidativestress in aged SAMP8 mice. J. Neurochem., 2003; 84: 1173-1183
  Google Scholar
• 30. Fernández-Galilea M., Prieto-Hontoria P.L., Martínez JA, Moreno-Aliaga M.J.: Antiobesity effects of α-lipoic acid supplementation.Clin. Lipidol., 2013; 8: 371-383
  Google Scholar
• 31. Fujita K., Nishizawa H., Funahashi T., Shimomura I., and ShimabukuroM.: Systemic oxidative stress is associated with visceral fataccumulation and the metabolic syndrome. Circ. J., 2006; 70: 1437-1442
  Google Scholar
• 32. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y.,Nakajima Y., Nakayama O., Makishima M., Matsuda M., ShimomuraI.: Increased oxidative stress in obesity and its impact on metabolicsyndrome. J. Clin. Invest., 2004; 114: 1752-1761
  Google Scholar
• 33. Gleiter C.H., Schug B.S., Hermann R., Elze M., Blume H.H.,Gundert-Remy U.: Influence of food intake on the bioavailabilityof thioctic acid enantiomers (letter). Eur. J. Clin. Pharmacol., 1996;50: 513-514
  Google Scholar
• 34. Goraca A., Huk-Kolega H., Kleniewska P., Piechota-Polanczyk A.,Skibska B.: Effects of lipoic acid on spleen oxidative stress after LPSadministration. Pharmacol. Rep., 2013; 65: 179-186
  Google Scholar
• 35. Goraca A., Huk-Kolega H., Kowalczyk A., Skibska B.: Anti-oxidativeand anti-inflammatory effects of lipoic acid in rat liver. PostępyHig. Med. Dośw., 2015; 69: 270-276
  Google Scholar
• 36. Grasso S., Bramanti V., Tomassoni D., Bronzi D., Malfa G.,Traini E., Napoli M., Renis M., Amenta F., Avola R.: Effect of lipoicacid and α-glyceryl-phosphoryl-choline on astroglial cellproliferation and differentiation in primary culture. J. Neurosci.Res., 2014; 92: 86–94
  Google Scholar
• 37. Han T., Bai J., Liu W., Hu Y.: Systematic review and meta–analysis of α-lipoic acid in the treatment of diabetic peripheralneuropathy. Eur. J. Endocrinol. 2012; 167: 465–471
  Google Scholar
• 38. Heitzer T., Finckh B., Albers S., Krohn K., Kohlschutter A.,MeinertzT.: Beneficial effects of α-lipoic acid and ascorbic acidon endothelium-dependent, nitric oxide-mediated vasodilationin diabetic patients: relation to parameters of oxidative stress.Free Radic. Biol. Med., 2001; 31: 53–61
  Google Scholar
• 39. Hinkle W., Cordell M., Leibel R., Rosenbaum M., Hirsch J.: Effects ofreduced weight maintenance and leptin repletion on functional connectivityof the hypothalamus in obese humans. PLoS One, 2013; 8: e59114
  Google Scholar
• 40. Huang Y.P., Jin H.Y., Yu H.P.: Inhibitory effects of α-lipoic acidon oxidative stress in the rostral ventrolateral medulla in rats withsalt-induced hypertension. Int. J. Mol. Med., 2017; 39: 430–436
  Google Scholar
• 41. Huerta A.E., Navas-Carretero S., Prieto-Hontoria P.L., MartınezJ.A., Moreno-Aliaga M.J.: Effects of α-lipoic acid and eicosapentaenoicacid in overweight and obese women during weight loss. Obesity,2015; 23: 313–321
  Google Scholar
• 42. Huerta A.E., Prieto-Hontoria P.L., Sainz N., Martınez J.A., Moreno-Aliaga M.J.: Supplementation with α-lipoic acid alone or incombination with eicosapentaenoic acid modulates the inflammatorystatus of healthy overweight or obese women consuming anenergy-restricted diet. J. Nutr., 2016; 146: 889S–896S
  Google Scholar
• 43. Jacob S., Ruus P., Hermann R., Tritschler H.J., Maerker E., RennW., Augustin H.J., Dietze G.J., Rett K.: Oral administration of RAC-α-lipoic acid modulates insulin sensitivity in patients with type-2diabetes mellitus: a placebo-controlled pilot trial. Free Radic. Biol.Med., 1999; 27: 309–314
  Google Scholar
• 44. Jiang T., Yin F., Yao J., Brinton R.D., Cadenas E.: Lipoic acid restoresage-associated impairment of brain energy metabolism throughthe modulation of Akt/JNK signaling and PGC1α transcriptional pathway.Aging Cell, 2013; 12: 1021–1031
  Google Scholar
• 45. Kandeil M.A., Amin K.A., Hassanin K.A., Ali K.M., MohammedE.T.: Role of lipoic acid on insulin resistance and leptin in experimentallydiabetic rats. J. Diabetes Complications, 2011; 25: 31–38
  Google Scholar
• 46. Keipert S., Jastroch M.: Brite/beige fat and UCP1 – is it thermogenesis?Biochim. Biophys. Acta, 2014; 1837: 1075–1082
  Google Scholar
• 47. Kim M.S., Park J.Y., Namkoong C., Jang P.G., Ryu J.W., Song H.S.,Yun J.Y., Namgoong I.S., Ha J., Park I.S., Lee I.K., Viollet B., Youn J.H.,Lee H.K., Lee K.U.: Anti-obesity effects of α-lipoic acid mediated bysuppression of hypothalamic AMP-activated protein kinase. Nat.Med., 2004; 10: 727–733
  Google Scholar
• 48. Koh E.H., Lee W.J., Lee S.A., Kim E.H., Cho E.H., Jeong E., Kim D.W.,Kim M.S., Park J.Y., Park K.G., Lee H.J., Lee I.K., Lim S., Jang H.C., LeeK.H., Lee K.U.: Effects of α-lipoic acid on body weight in obese subjects.Am. J. Med., 2011; 124: 85.e1–8
  Google Scholar
• 49. Koriyama Y., Nakayama Y., Matsugo S., Kato S.: Protective effectof lipoic acid against oxidative stress is mediated by Keap1/Nrf2-dependentheme oxygenase-1 induction in the RGC-5 cell line. BrainRes., 2013; 1499: 145–157
  Google Scholar
• 50. Kucukgoncu S., Zhou E., Lucas K.B., Tek C.: α-lipoic acid (ALA) asa supplementation for weight loss: results from a meta-analysis ofrandomized controlled trials. Obes. Rev., 2017; 18: 594–601
  Google Scholar
• 51. Lafontan M.L.: Adipose tissue and adipocyte dysregulation. DiabetesMetab., 2014; 40: 16–28
  Google Scholar
• 52. Lee K.W., Pausova Z.: Cigarette smoking and DNA methylation.Front. Genet., 2013; 4: 132
  Google Scholar
• 53. Li G., Fu J., Zhao Y., Ji K., Luan T., Zang B.: α-lipoic acid exertsanti-inflammatory effects on lipopolysaccharide- stimulated ratmesangial cells via inhibition of nuclear factor kappa B (NF-κb) signalingpathway. Inflammation, 2015; 38: 510–519
  Google Scholar
• 54. Lukaszuk J.M., Schultz T.M., Prawitz A.D., Hofmann E.: Effects ofR-α lipoic acid on HbA1c, lipids and blood pressure in Type-2 diabetics:A preliminary study. J. Complement. Integr. Med., 2009; 6: 1–14
  Google Scholar
• 55. Malińska D., Winiarska K.: Kwas liponowy – charakterystyka izastosowanie w terapii. Postępy Hig. Med. Dośw., 2005; 59: 535–543
  Google Scholar
• 56. Mansego M.L., Milagro F.I., Zulet M.A., Moreno-Aliaga M.J., MartinezJ.A.: Differential DNA methylation in relation to age and healthrisks of obesity. Int. J. Mol. Sci., 2015; 16: 16816–16832
  Google Scholar
• 57. McMackin C.J., Widlansky M.E., Hamburg N.M., Huang A.L., WellerS., Holbrook M., Gokce N., Hagen T.M., Keaney J.F. Jr., Vita J.A.:Effect of combined treatment with α lipoic acid and acetyl-L-carnitineon vascular function and blood pressure in coronary arterydisease patients. J. Clin. Hypertens, 2007; 9: 249–255
  Google Scholar
• 58. Micili S.C., Ergur B.U., Ozoğul C., Saroioglu S., Bagryianik H.A.,Tugyan K., Pekcetin C., Sonmez U., Tekmen I., Erbil G., Akdogan G.G.,Ozyurt D., Buldan Z.: Effects of lipoic acid in an experimentally inducedhypertensive and diabetic rat model. Clin. Exp. Hypertens.,2013; 35: 373–381
  Google Scholar
• 59. Midaoui A.E., Elimadi A., Wu L., Haddad P.S., de Champlain J.:Lipoic acid prevents hypertension, hyperglycemia, and the increasein heart mitochondrial superoxide production. Am. J. Hypertens.,2003; 16: 173–179
  Google Scholar
• 60. Midaoui A.E., Talbot S., Lahjouji K., Dias J.P., Fantus I.G., CoutureR.: Effects of α-lipoic acid on oxidative stress and kinin receptorexpressionin obese Zucker diabetic fatty rats. J. Diabetes Metab.,2015; 6: 1–7
  Google Scholar
• 61. Milagro F.I., Mansego M.L., de Miguel C., Martinez, J.A.: Dietaryfactors, epigenetic modifications and obesity outcomes: Progressesand perspectives. Mol. Aspects Med., 2013; 34: 782–812
  Google Scholar
• 62. Mohammadi V., Khalili M., Eghtesadi S., Dehghani S., JazayeriS., Aghababaee S.K., Sabour H., Saberi H., Eghtesadi M., Gohari M.R.:The effect of α-lipoic acid (ALA) supplementation on cardiovascularrisk factors in men with chronic spinal cord injury: a clinical trial.Spinal Cord., 2015; 53: 621–624
  Google Scholar
• 63. Moini H., Packer L., Saris N.E.: Antioxidant and prooxidant activitiesof α-lipoic acid and dihydrolipoic acid. Toxicol. Appl. Pharmacol.,2002; 182: 84–90
  Google Scholar
• 64. Monastra G, De Grazia S, Cilaker Micili S., Goker A., Unfer V.:Immunomodulatory activities of α lipoic acid with a special focuson its efficacy in preventing miscarriage. Expert. Opin. Drug Deliv.,2016, 13: 1695–1707
  Google Scholar
• 65. Muellenbach E.A., Diehl C.J., Teachey M.K., Lindborg K.A., ArchuletaT.L., Harrell N.B., Andersen G., Somoza V., Hasselwander O., MatuschekM., Henriksen E.J.: Interactions of the advanced glycation end productinhibitor pyridoxamine and the antioxidant α-lipoic acid on insulinresistance in the obese Zucker rat. Metabolism, 2008; 57: 1465–1472
  Google Scholar
• 66. Namazi N., Larijani B., Azadbakht L.: α-lipoic acid supplement inobesity treatment: A systematic review and meta-analysis of clinicaltrials. Clin. Nutr., 2018; 37: 419–428
  Google Scholar
• 67. Okudan N., Nurullahoglu Atalik K.E., Gokbel H., Canbilen A.,Kara I.: α lipoic acid treatment improved endothelium-dependentrelaxation in diabetic rat aorta. Yakugaku Zasshi, 2011; 131: 739–744
  Google Scholar
• 68. Ou P., Tritschler H.J., Wolff S.P.: Thioctic (lipoic) acid: a therapeuticmetal-chelating antioxidant? Biochem. Pharmacol., 1995; 50: 123–126
  Google Scholar
• 69. Packer L., Roy S., Sen C.K.: α-lipoic acid: A metabolic antioxidantand potential redox modulator of transcription. Adv. Pharmacol.,1997; 38: 79–101
  Google Scholar
• 70. Park S., Karunakaran U., Jeoung N.H., Jeon J.H., Lee I.K.: Physiologicaleffect and therapeutic application of α lipoic acid. Curr. Med.Chem., 2014; 21: 3635–3645
  Google Scholar
• 71. Pompella A., Visvikis A., Paolicchi A., De Tata V., Casini A.F.:The changing faces of glutathione, a cellular protagonist. Biochem.Pharmacol., 2003; 66: 1499–1503
  Google Scholar
• 72. Prieto-Hontoria P.L., Perez-Matute P., Fernandez-Galilea M., BarberA., Martınez J.A., Moreno-Aliaga M.J.: Lipoic acid prevents bodyweight gain induced by a high fat diet in rats: Effects on intestinalsugar transport. J. Physiol. Biochem., 2009; 65: 43–50
  Google Scholar
• 73. Quinn J.F., Bussiere J.R., Hammond R.S., Montine T.J., Henson E.,Jones R.E., Stackman R.W., Jr.: Chronic dietary α-lipoic acid reducesdeficits in hippocampal memory of aged Tg2576 mice. Neurobiol.Aging, 2007; 28: 213–225
  Google Scholar
• 74. Radke G.A., Ono K., Ravindran S., Roche T.E.: Critical role of alipoyl cofactor of the dihydrolipoyl acetyltransferase in the bindingand enhanced function of the pyruvate dehydrogenase kinase. Biochem.Biophys. Res, Commun., 1993; 190: 982–991
  Google Scholar
• 75. Rahman S.T., Merchant N., Haque T., Wahi J., Bhaheetharan S.,Ferdinand K.C., Khan BV.: The impact of lipoic acid on endothelialfunction and proteinuria in quinapril-treated diabetic patients withstage I hypertension: Results from the QUALITY study. J. Cardiovasc.Pharmacol. Ther., 2012; 17: 139–145
  Google Scholar
• 76. Rochette L., Ghibu S., Muresan A., Vergely C.: α-lipoic acid: Molecularmechanisms and therapeutic potential in diabetes. Can. J.Physiol. Pharmacol., 2015; 93: 1021–1027
  Google Scholar
• 77. Roman-Pintos L.M., Villegas-Rivera G., Rodriguez-CarrizalezA.D., Miranda-Diaz A., Cardona-Munoz E.G.: Diabetic polyneuropathyin type 2 diabetes mellitus: inflammation, oxidative stress andmitochondrial function. J. Diabetes Res., 2016; 2016: 3425617
  Google Scholar
• 78. Roy S., Praneetha D.C., Vendra V.P.: Mutations in the corneal endothelialdystrophy-associated gene SLC4A11 render the cells morevulnerable to oxidative insults. Cornea, 2015; 34: 668–674
  Google Scholar
• 79. Scaramuzza A., Giani E., Redaelli F., Ungheri S., Macedoni M.,Giudici V., Bosetti A., Ferrari M., Zuccotti G.V.: α-lipoic acid and antioxidantdiet help to improve endothelial dysfunction in adolescentswith type 1 diabetes: A pilot trial. J. Diabetes Res., 2015; 2015: 474561
  Google Scholar
• 80. Shay K.P., Michels A.J., Li W., Kong A.N., Hagen T.M.: Cap-independentNrf2 translation is part of a lipoic acid-stimulated detoxificationstress response. Biochim. Biophys. Acta, 2012; 1823: 1102–1109
  Google Scholar
• 81. Sola S., Mir M.Q., Cheema F.A., Khan-Merchant N., MenonR.G., Parthasarathy S., Khan B.V.: Irbesartan and lipoic acid improveendothelialfunction and reduce markers of inflammationin the metabolicsyndrome: results of the Irbesartan and LipoicAcid in endothelialdysfunction (ISLAND) study. Circulation,2005; 111: 343–348
  Google Scholar
• 82. Song K.H., Lee W.J., Koh J.M., Kim H.S., Youn J.Y., Park H.S., KohE.H., Kim M.S., Youn J.H., Lee K.U., Park J.Y.: α-Lipoic acid preventsdiabetes mellitus in diabetes-prone obese rats. Biochem. Biophys.Res. Commun., 2005; 326: 197–202
  Google Scholar
• 83. Stepanovic-Petrovic R., Micov A., Tomic M., Pecikoza U.: Levetiracetamsynergizes with gabapentin, pregabalin, duloxetine andselected antioxidants in a mouse diabetic painful neuropathy model.Psychopharmacology, 2017; 234: 1781–1794
  Google Scholar
• 84. Sugimoto K., Yasujima M., Yagihashi S.: Role of advanced glycationend products in diabetic neuropathy. Curr. Pharm. Des., 2008;14: 953–961
  Google Scholar
• 85. Tanaka Y., Kaibori M., Miki H., Nakatake R., Tokuhara K., NishizawaM., Okumura T., Kwon A.H.: α-lipoic acid exerts a liver-protectiveeffect in acute liver injury rats. J. Surg. Res., 2015; 193: 675–683
  Google Scholar
• 86. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., TelserJ.: Free radicals and antioxidants in normal physiological functionsand human disease. Int. J. Biochem. Cell Biol., 2007; 39: 44–84
  Google Scholar
• 87. Vasdev S., Ford C.A., Parai S., Longerich L., Gadag V.: Dietaryα-lipoic acid supplementation lowers blood pressure in spontaneouslyhypertensive rats. J. Hypertens., 2000; 18: 567–573
  Google Scholar
• 88. Wada H., Shintani D., Ohlrogge J.: Why do mitochondria synthesizefatty acids? Evidence for involvement in lipoic acid production.Proc. Natl. Acad. Sci. USA, 1997; 94: 1591-1596
  Google Scholar
• 89. Widlansky M.E., Gokce N., Keaney J.F.Jr, Vita J.A.: The clinicalimplicationsof endothelial dysfunction. J. Am. Coll. Cardiol., 2003;42: 1149-1160
  Google Scholar
• 90. World Health Organization (WHO). Obesity: Preventing andmanaging the global epidemic. Report of a WHO consultation. WHOTechnical Report Series, 2000; 894: 1-253
  Google Scholar
• 91. Ying Z., Kampfrath T., Sun Q., Parthasarathy S., Rajagopalan S.:Evidence that α-lipoic acid inhibits NF-κB activation independent ofits antioxidant function. Inflamm. Res., 2011; 60: 219-225
  Google Scholar
• 92. Yorek M.S., Obrosov A., Shevalye H., Coppey L.J., Kardon R.H.,Yorek M.A.: Early vs. late intervention of high fat/low dose streptozotocintreated C57BI/6J mice with enalapril, α-lipoic acid, menhadenoil or their combination: effect on diabetic neuropathy relatedendpoints. Neuropharmacology, 2017; 116: 122-131
  Google Scholar
• 93. Yu X., Liu H., Zou J., Zhu J., Xu X., Ding X.: Oxidative stress in5/6 nephrectomizedrat model: effect of α-lipoic acid. Ren Fail.,2012; 34: 907-914
  Google Scholar
• 94. Zhang J., McCullough P.A.: Lipoic acid in the prevention of acutekidney injury. Nephron, 2016; 134: 133-134
  Google Scholar
• 95. Zhang S., Li H., Zhang L., Li J., Wang R, Wang M.: Effects of troxerutinon cognitive deficits and glutamate cysteine ligase subunits inthe hippocampus of streptozotocin-induced type 1 diabetes mellitusrats. Brain Res., 2017; 1657: 355-360
  Google Scholar
• 96. Zhang Y., Han P., Wu N., He B., Lu Y., Li S., Liu Y., Zhao S., Liu L., LiY.: Amelioration of lipid abnormalities by α-lipoic acid through antioxidativeand anti-inflammatory effects. Obesity, 2011; 19: 1647–1653
  Google Scholar
• 97. Zhang Y.H., Wang D.W., Xu S.F., Zhang S., Fan Y.G., Yang Y.Y., Guo S.Q.,Wang S., Guo T., Wang Z.Y., Guo C.: α-Lipoic acid improves abnormal behaviorby mitigation of oxidative stress, inflammation, ferroptosis, andtauopathy in P301S Tau transgenic mice. Redox Biol., 2018; 14: 535–548
  Google Scholar
• 98. Zhao L., Hu F.X.: α-lipoic acid treatment of aged type 2 diabetesmellitus complicated with acute cerebral infarction. Eur. Rev. Med.Pharmacol. Sci., 2014; 18: 3715–3719
  Google Scholar
• 99. Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A.,Munzel U., Yakhno N., Raz I., Novosadova M., Maus J., Samigullin R.:Oral treatment with α-lipoic acid improves symptomatic diabeticpolyneuropathy. Diabetes Care, 2006; 29: 2365–2370
  Google Scholar
• 100. Ziegler D., Low P.A., Litchy W.J., Boulton A.J., Vinik A.I., FreemanR., Samigullin R., Tritschler H., Munzel U., Maus J., Schutte K.,Dyck P.J.: Efficacy and safety of antioxidant treatment with α-lipoicacid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.Diabetes Care, 2011; 34: 2054–2060
  Google Scholar

Pełna treść artykułu